Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for benidipine hydrochloride tablets approved and issued by the State Drug Administration. Benidipine hydrochloride tablets are used to treat essential hypertension, angina pectoris. Benidipine hydrochloride tablets were first developed by Kyowa Hakko Kirin Co., Ltd., and marketed in Japan in October 1991, and approved for domestic marketing in March 2004.

According to relevant national policies, the current production of benidipine hydrochloride tablets according to Class 4 chemicals can be considered to have passed the consistency evaluation. The approval of this product further enriches the company's product line and helps enhance the company's market competitiveness.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.